Radiation with helical tomotherapy before stem cell transplant
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial studies a specific type of radiation (helical tomotherapy) in people with multiple myeloma who are planning an autologous stem cell transplant. It may help the study team understand how safe and effective this approach is when used during transplant preparation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma and are currently doing induction treatment and getting ready to collect stem cells for your own transplant
- You can follow the study’s birth control (contraception) rules during the trial
- Your performance status is ECOG 2 or better (you can generally do daily activities with limited assistance)
- Your blood tests and liver/kidney markers are high enough (bilirubin, ALT, AST within limits; kidney function okay), and your neutrophils and platelets meet minimum levels
- You collected at least 2 million CD34+ stem cells per kilogram (part of stem cell mobilization for transplant)
- You are expected to live more than 3 months and can provide informed consent (you or a close family member)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a specific chemotherapy combination (thiotepa and melphalan) given before a stem cell transplant to treat multiple myeloma. The study compares this approach to help doctors understand if it improves outcomes for patients whose myeloma hasn't fully responded to initial treatment.
This trial tests whether the chemotherapy medicine treosulfan (Trecondi® Ideogen) works well and is safe for people with myeloma who are moving on to high-dose chemotherapy plus their own stem cell transplant. It may help strengthen the transplant “conditioning” treatment before the transplant.
This trial tests adding siltuximab to standard melphalan chemotherapy before a stem cell transplant. It is for people with multiple myeloma who are 60 or older and having a transplant within the first year of diagnosis.
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
This study combines a stem cell transplant with a special immune therapy (CAR-T) to treat multiple myeloma that is very aggressive and has not responded well to initial treatments. The goal is to see if this combination can better control the cancer.
This early-phase study tests an injected radioactive antibody (211At-OKT10-B10) given before donor stem cell transplant, alone or with chemotherapy and low-dose body radiation. It is meant for people with high-risk multiple myeloma to see if the treatment can better prepare the body for the transplant and improve outcomes.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.